At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
BI 3006337 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Subcutaneous Doses and Multiple Subcutaneous Doses Over 6 Weeks of BI 3006337 in Healthy Male Japanese Subjects (Single-blind, Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)
In Brief
A Phase 1 clinical trial evaluating BI 3006337 and Placebo for Healthy. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BI 3006337 in healthy male subjects following s.c. administration of single rising doses and multiple doses over 6 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedMar 2024
Enrollment StartApr 2024
Primary CompletionOct 2024
TodayJul 2026
First PostedMar 13, 2024
Enrollment StartApr 19, 2024
Primary CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.3 years ago
Interventions
BI 3006337drug
BI 3006337
Placebodrug
Placebo